Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
about
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsUsing large-scale genomics data to identify driver mutations in lung cancer: methods and challengesResponse of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapiesTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsOpen pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell linesA design principle underlying the paradoxical roles of E3 ubiquitin ligasesRas oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancerRNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs.Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.Targeting survivin in cancer: novel drug development approaches.Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomasIntratumoral heterogeneity in a minority of ovarian low-grade serous carcinomasAcquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loopCDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical CancerTargeting Histone Deacetylases in Diseases: Where Are We?Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptationsNucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapAAdvanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma.Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms.Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells.ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Focus on Nintedanib in NSCLC and Other TumorsAZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.The controversial role of phospholipase C epsilon (PLCε) in cancer development and progression.Emerging drugs for cervical cancer.Oncogene and non-oncogene addiction in inflammation-associated cancers.Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target.
P2860
Q26774625-584C4F4C-A086-49E5-A820-091FB23B08F7Q26782539-DBC336A4-59D8-48F9-803A-7C1E3002AFB4Q26800833-A02C262C-5FBC-49D2-AF90-7B0EE8A8AAE8Q27853149-58204188-DE03-4251-81B6-39487AF904EAQ28076462-363607FB-A346-44C6-A77C-B52095FE671EQ28598343-170235BA-9FAF-47EB-8C51-74D939A6976FQ28650700-C93D2B7E-3DFA-4FCD-9B3D-038E08BE1DB8Q30844250-8E0548A0-45D6-4181-A6F6-8DE4CB4A1A95Q33779805-EC2FC82D-318E-4E05-AE83-E3AB75D4242DQ33943271-CE733EFB-5D11-44CA-9930-CAF93D9C92C8Q34439333-ADA5F463-8F08-41B4-B699-B0B47821D0B6Q34495445-C5815ECA-136D-4E3A-AD7E-C45C700DA488Q34584632-2F88A879-7337-4ED1-87D4-408F928CE812Q34755104-BB0BEC43-2C0A-40C4-AC33-FB0F88C857A9Q34954296-D5856C55-47E9-45C4-A675-9E7CD78651CAQ35018167-D4A20830-F758-4313-B304-F8EB697ADF45Q35060446-4241EAA0-A98E-4E5D-AA0E-72254D75684EQ35741610-47F3F002-6F99-4501-960F-61493029FF21Q35776083-DF507BE5-6F09-45F0-AF57-70251FFA6A76Q35821728-C41952F9-6499-42C0-83CF-089D650B194AQ36317659-402DA366-BD39-42FF-8274-04B3DD71BB1BQ36367297-E80B8459-6A3C-495F-BBA2-6CAD8D6CF8FFQ36414976-BE5251EA-165A-4A78-8C3C-22968D99A5ACQ36545083-EC3D7332-D407-46EC-992D-4879EAA8CBBCQ36589753-18D3D684-6DF0-4DBE-AF6C-6D22C263FA41Q36721273-365AF08D-4D03-43B1-B186-4EBB4664DF32Q36849676-12200573-A318-4F31-ACA6-FE71CB8912FEQ36925197-62EA5992-67A8-4E6E-B211-C16D2F0742D5Q37164683-08043B6C-69B4-4464-B4A6-DF34457D1A3BQ37225520-46B2D7E6-5DFA-4C10-8876-3A9F7692F227Q37379680-FC6AE612-837D-453C-831B-32DE70FF3E5DQ37512962-95F470F9-B1E9-4C99-A72D-E642F2EACEBAQ37613445-27E86B4A-0CEF-4E2A-A8F9-6E594C944245Q37687424-C10C89F7-9712-4ED2-85BC-26E66F543BA7Q37708952-A61587ED-EF5B-4646-AC86-230FEF3506C5Q37738063-D5364000-ADB6-42FE-A2DD-50E0CEAE29CAQ38005222-CC039038-5094-43BA-8944-84969DE2A329Q38096415-652E081F-48CF-4985-AE54-EB0D332AD929Q38187388-544D961D-3A91-475B-AE6D-A9AD3B4452A0Q38209122-44C6EFE0-214F-4888-BC65-0306A581F863
P2860
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Oncogene addiction as a founda ...... r therapy: promises and perils
@ast
Oncogene addiction as a founda ...... r therapy: promises and perils
@en
type
label
Oncogene addiction as a founda ...... r therapy: promises and perils
@ast
Oncogene addiction as a founda ...... r therapy: promises and perils
@en
prefLabel
Oncogene addiction as a founda ...... r therapy: promises and perils
@ast
Oncogene addiction as a founda ...... r therapy: promises and perils
@en
P2860
P356
P1476
Oncogene addiction as a founda ...... r therapy: promises and perils
@en
P2093
Davide Torti
Livio Trusolino
P2860
P304
P356
10.1002/EMMM.201100176
P577
2011-09-23T00:00:00Z
2011-11-01T00:00:00Z